Nitrazepam is an antiepileptic drug that may induce upper airway hypersecretion. The objective of this study is to evaluate the frequency of nitrazepam induced drooling and aspiration in children with epilepsy.
Introduction
Nitrazepam is antiepileptic drug used in several types of epilepsy. There are reports of its association with upper airway hypersecretion, especially in children (1). Therefore, aspiration and pneumonia may occur (2). The objective of this study was to evaluate the occurrence of upper airway abnormalities in children with epilepsy in use of nitrazepam.
Results and Discussion
This study was conducted at the pediatric epilepsy clinic of Hospital das Clínicas da Unicamp. Twenty patients were included. The data was compared with a disease control group of children with epilepsy without any current use of any type of benzodiazepine. Twelve were boys and 8 were girls, aged between 5 months-old and 17 yearsold (mean age of 3.97 years). In the control group 8 were boys and 12 girls, ages between 1 yearold and 18 years-old (mean 8.24 years). All patients had refractory epilepsy. After introduction of nitrazepam 2 patients became seizure free; 13 had an improvement of more than 75% control; and two an improvement of more than 50% in seizure control. Three patients had no improvement in seizure control.
Because most patients presented a great improvement in seizure control, nitrazepam was not tapered off due to upper airway abnormalities. Most families chose to increase pulmonary physical therapy in order to improve pulmonary symptoms.
Conclusions
Children with epilepsy in use of nitrazepam have an increase risk of drooling, aspiration and upper airway adverse effects. The risk of serious pulmonary complications should be carefully evaluated before prescribing this drug.
